Showing 1894 results
April 2024
-
Story People and Culture
From black holes to AI driven drug discovery – collaboration wins the day
Dr Bülent Kızıltan, Global Head of AI & Computational Sciences
-
Press release
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic… -
Press release
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic… -
Ad hoc release
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Ad hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD)Key growth drivers continued strong sales momentum including Entresto… -
Ad hoc release
Novartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024
Annonce événementielle au sens de l’art. 53 RCRésultats du premier trimestre (T1)Chiffre d’affaires net en hausse de +11% (tcc1, +10% USD) et du résultat opérationnel core, de +22% (tcc, +16% USD)… -
Ad hoc release
Novartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im ersten Quartal um +11% (kWk1, +10% USD), das operative Kernergebnis verbesserte sich um +22% (kWk, +16% USD)Die wichtigsten… -
Press release
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis… -
Press release
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare… -
Press release
Novartis tender offer for MorphoSys AG commences
Basel, April 11, 2024 – Novartis published today the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG… -
Pulse Update
Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2
-
Story From Our Labs
Drug delivery, service delivery, and the future of cancer care
State-of-the-art Novartis manufacturing facility in Indianapolis fortifies the foundation of an entirely new paradigm in pharmaceutical drug delivery.